

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 67781

Title: Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02936638

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: China

Manuscript submission date: 2021-05-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-07 00:10

Reviewer performed review: 2021-05-10 11:48

Review time: 3 Days and 11 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The present study was well organized or reviewed adverse GI symptoms or hepatic injury related to COVID-19 treatment drugs and vaccines. The treatment drugs and vaccines for COVID-19 give a lot of information for us.

PEER-REVIEW REPORT

Name of journal: *World Journal of Hepatology*

Manuscript NO: 67781

Title: Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02527808

Position: Editor-in-Chief

Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2021-05-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-06 22:54

Reviewer performed review: 2021-05-13 23:19

Review time: 7 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The submitted article is valuable as regard it try to discuss the GIT and hepatic side effects of drugs and vaccines used for treatment of COVID-19 patients with chronic liver diseases, but some comments to be considered: 1- it is better to enlist drugs used in COVID-19 according to the life cycle of the virus to detect potential targets for drug therapy (Promising drug targets include nonstructural proteins (eg, 3-chymotrypsin-like protease, papain-like protease, RNA-dependent RNA polymerase), which share homology with other novel coronaviruses (nCoVs). Additional drug targets include viral entry and immune regulation pathways.) 2- many drugs were not listed or discussed i- Umifenovir (Arbidol) which inhibit S protein/ACE2, membrane fusion inhibitor (200 mg every 8h by mouth 7-14 d. Available as: 50-mg and 100-mg tablets, capsules and granules. Dose adjustments: Kidney: no dose adjustment necessary. Hepatic: No specific recommendations available, caution in those with hepatic impairment. ii- Favipiravir:

RNA polymerase inhibitor Exclusion criteria based Hyperuricemia, diarrhea, elevated transaminases. iii- Nitazoxanide, traditionally an antihelminthic agent, has broad antiviral activity and a relatively favorable safety profile. Nitazoxanide has demonstrated in vitro antiviral activity against MERS and SARS-CoV-2. 58,59 Pending further evidence, the antiviral activity, immunomodulatory effects, and safety profile of nitazoxanide warrant its further study as a treatment option for SARS-CoV-2. iv- Ivermectin: Ivermectin is thought to block the cargo transporter which means the virus can't get into the nucleus, and so can't make copies of itself. A very interesting clinical trial using combinations of these drugs not cited (Hatem Elalfy , Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

(MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021 :1-8 doi: 10.1002/jmv.26880. Online ahead of print. PMID: 33590901. v-Molnupiravir is an antiviral drug that is in clinical trials aiming to treat coronavirus. It's been said that it has shown some use against other viruses such as SARS and MERS. Its been designed to treat deaths and hospitalizations, but it also prevents transmission. vi-Bromhexine as the drug with the strongest inhibitory effect on TMPRSS2. It can be used to block pulmonary virus infection, A large number of sticky secretions have been seen in the autopsy lung sections of COVID-19 patients who have died. 3- As regard COVID-19 vaccines and chronic liver diseases :there is no specefic side effects or complications , the discussion is vague not give any specific conclusions e.g reference 119 page 19 (Each study group included 596618 persons, and the vaccinated population included 9699 (1.6%) patients with liver disease and 435 (0.1%) patients with solid organ transplantation [119].???? where the results of the study as regard these liver group??